Directorio independiente

Centro de Investigación Clínica de Oaxaca

Oaxaca. Esta página agrupa registros donde ClinicalTrials.gov publica nombres de sede que coinciden con este centro dentro de las condiciones que monitoreamos.

Perfil informativo no verificado por el centro

Construido a partir de registros públicos; no implica afiliación.

Sin afiliación: BiomedicalResearch.mx no afirma representar a este centro y no garantiza que este listado sea completo. Confirma siempre nombre, dirección, contacto y estatus en el registro oficial.

Variantes de nombre encontradas

  • Centro de Investigacion Clinica de Oaxaca
  • Centro de Investigacion Clinica de Oaxaca ( Site 0509)
  • Centro de Investigacion Clinica de Oaxaca ( Site 0543)
  • Centro de Investigacion Clinica de Oaxaca ( Site 0601)
  • Centro de Investigacion Clinica de Oaxaca ( Site 0813)
  • Centro de Investigacion Clinica de Oaxaca ( Site 0934)
  • Centro de Investigacion Clinica de Oaxaca ( Site 1109)
  • Centro de Investigacion Clinica de Oaxaca ( Site 2503)

Estudios detectados

ReclutandoNCT07062965

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Fase 3Pfizer
Ver registro oficial ↗
ReclutandoNCT07405801

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Fase 2Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Fase 3Merck Sharp & Dohme LLC
Ver ficha informativa
ReclutandoNCT07060807

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Fase 3Hoffmann-La Roche
Ver registro oficial ↗
ReclutandoNCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Fase 3Merck Sharp & Dohme LLC
Ver ficha informativa
ReclutandoNCT06925737

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Fase 3Merck Sharp & Dohme LLC
Ver ficha informativa
ReclutandoNCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT07190248

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Fase 3Pfizer
Ver registro oficial ↗
ReclutandoNCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Fase 3Eli Lilly and Company
Ver ficha informativa
ReclutandoNCT06312137

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Fase 3Merck Sharp & Dohme LLC
Ver registro oficial ↗
ReclutandoNCT05920356

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Fase 3Amgen
Ver registro oficial ↗